Background : C MYC, BCL2 and CD30 play an important role in ‎initiation and propagation of diffuse large B-cell lymphoma ‎‎(DLBCL). Protein expression of these marker were used in the ‎diagnosis, predicting the prognosis and as a therapeutic target in ‎DLBCL
purpose: this study aimed to assess the prognostic impact and ‎therapeutic utility of expression patterns of CD30, BCL2, MYC in ‎DLBCL
Patients and Methods: ‎
This retrospective study was carried out on DLBCL ‎diagnosed at Oncology Centre Mansoura University (2016-2019). ‎The study was approved by IRB of Mansoura faculty of Medicine ‎Code Number: R.23.01.2043, 21/03/2023.‎
Results: BCL2, C MYC, concurrent BCL2,C MYC and CD30 ‎overexpression was present in 76%, 36%,, 26% and 26% of the ‎studied cases respectively. Concurrent expressions of BCL2, C ‎MYC showed significant association with the presence relapse (P= ‎‎0.003). concurrent expression of BCL2, C MYC revealed ‎significant association with the progressive therapy response ‎‎(P=0.003). In addition, C MYC, expression was significantly ‎associated with the presence of exranodal presentation (P=0.03). ‎CD30 protein overexpression was significantly associated with ‎stage II and III (P=0.03). CD30 positivity showed inverse ‎correlation with the concurrent expression of BCL2, C MYC ‎‎(Correlation Coefficient=--.355, P=0,02). Also CD30 positivity ‎and concurrent expression of BCL2, C MYC reflected significant ‎prognostic impact on overall survival (OS) and disease free survival ‎‎(DFS) (all P=0.00).‎
Conclusion: concurrent C MYC, BCL2 overexpression is ‎associated with a lower OS, and DFS. CD30 positivity is ‎associated with a better OS, and DFS which can be utilized in ‎management plan of DLBCL.‎